PT Indofarma Tbk (ISX:INAF) Beta: -0.0955 (As of Jun. 25, 2026)


ISX:INAF PT Indofarma Tbk ISX:INAF
8 GF Score
Price Rp126.00
GF Value Rp176.99
! 6 Warning Signs
View Full Analysis

What is PT Indofarma Tbk Beta?

PT Indofarma Tbk ISX:INAF 8 Beta is -0.0955 as of Jun. 25, 2026. GuruFocus rates ISX:INAF with a GF Score™ of 8/100 and a GF Value™ of Rp176.99. The stock has 6 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), PT Indofarma Tbk's Beta is -0.0955.


PT Indofarma Tbk  (ISX:INAF) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


PT Indofarma Tbk Beta Related Terms


PT Indofarma Tbk Beta Historical Data

* Premium members only.

The historical data trend for PT Indofarma Tbk's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Indofarma Tbk Beta Chart

PT Indofarma Tbk Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.78 -1.20 1.51 0.86 0.20

PT Indofarma Tbk Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.86 0.44 -0.12 -0.02 0.20

ISX:INAF vs ZTS, VTRS, NBIX: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PT Indofarma Tbk's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PT Indofarma Tbk Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PT Indofarma Tbk's Beta distribution charts can be found below:

* The bar in red indicates where PT Indofarma Tbk's Beta falls into.


ISX:INAF
8GF Score
PT Indofarma Tbk ISX:INAF
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PT Indofarma Tbk Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.0955 mean?
PT Indofarma Tbk (ISX:INAF) has a Beta of -0.0955 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for PT Indofarma Tbk and its competitors.
Is PT Indofarma Tbk's Beta too high?
PT Indofarma Tbk's current Beta is -0.0955. Overall, PT Indofarma Tbk has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does PT Indofarma Tbk's Beta compare to ZTS and VTRS?
PT Indofarma Tbk's Beta of -0.0955 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for PT Indofarma Tbk and its competitors. PT Indofarma Tbk's current Beta is -0.0955. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Indofarma Tbk stock overvalued right now?
PT Indofarma Tbk (ISX:INAF) has a current Beta of -0.0955. The stock's GF Value™ is Rp176.99, compared to a current price of Rp126.00 — trading 28.8% below its estimated fair value. The current Beta is -0.0955. PT Indofarma Tbk's overall GF Score™ is 8/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For PT Indofarma Tbk (ISX:INAF), the current Beta is -0.0955 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Indofarma Tbk (ISX:INAF) Overvalued in 2026?

Based on GuruFocus' analysis, PT Indofarma Tbk stock appears to be undervalued. The current stock price of Rp126.00 is trading 28.8% below its estimated GF Value™ of Rp176.99.

Key valuation signals for ISX:INAF:

  • Beta: -0.0955
  • GF Value™: Rp176.99 vs. price of Rp126.00 (28.8% below fair value)
  • GF Score™: 8/100 with 6 warning signs

No single metric tells the full story. See the ISX:INAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PT Indofarma Tbk Business Description

Address Jalan Indofarma No. 1, Cikarang Barat, Jawa Bara, Bekasi, IDN, 17530
PT Indofarma Tbk is a specialty and generic drug manufacturing company. The company has four business segments - Medicine, Medical Devices and others. The Medicine business segment includes drug production, marketing distribution, and sales. The Medical Device Segment includes medical devices and other products. Company generates majority revenue from the Medicine segment. The Company classifies its distribution segments based on geographic regions into six areas, namely Java, Sumatra, Kalimantan, Sulawesi, Bali dan West Nusa Tenggara (NTB),as well as the Eastern Indonesia region.
8GF Score

Get the complete analysis for ISX:INAF

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp126.00
Price
Rp176.99
GF Value